Common use of Code of Conduct Clause in Contracts

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK shall make adherence to the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includes, or within 120 days after the Effective Date shall be revised to address the following: a. GSK’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSK’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, and with GSK’s own Policies and Procedures; c. GSK’s requirement that all Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSK, suspected violations of any Federal health care program requirements, FDA requirements, or of GSK’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSK’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 90 days after the Effective Date, GSK Extendicare shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK Extendicare shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKExtendicare’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKExtendicare’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKExtendicare’s own Policies and ProceduresProcedures as implemented pursuant to Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of Extendicare’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKExtendicare, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKExtendicare’s own Policies and Procedures; d. the personal obligations requirement that all of each Extendicare’s Covered Person Persons shall immediately report to the Compliance Officer, or other appropriate individual designated by Extendicare, credible allegations of resident harm and such report shall be complete, full, and honest; e. the possible consequences to both Extendicare and Covered Persons of failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith Extendicare’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. f. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKExtendicare’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Extendicare’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Extendicare shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior LHC shall continue to the Effective Date, GSK developed adhere to and implemented a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written promote its Code of Conduct to all Covered Persons. GSK shall make adherence to the Code of Conduct and Ethics and use it as an element in evaluating the performance of all employees who are Covered Personsemployees. The LHC’s Code of Conduct includesand Ethics shall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKLHC’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKLHC’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKLHC’s own Policies and Procedures; c. GSK’s the requirement that all of LHC’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKLHC, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKLHC’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKLHC’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplishedSince June 1, within 2011, every LHC officer and employee has certified that he or she has received, read, understood, and shall abide by LHC’s Code of Conduct and Ethics. Within 120 days after of the Effective Date, each all Covered Person Persons shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the LHC’s Code of ConductConduct and Ethics. New Covered Persons shall receive the Code of Conduct and Ethics and shall complete the required certification within 30 60 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK LHC shall periodically review the Code of Conduct and Ethics to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct and Ethics shall be distributed within 30 60 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct and Ethics within 30 60 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementConduct and Ethics.

Code of Conduct. Prior Ensign Group represents that, prior to the Effective Date, GSK developed Ensign Group developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK Ensign Group shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKx. Xxxxxx Group’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKx. Xxxxxx Group’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKEnsign Group’s own Policies and Procedures; c. GSK’s the requirement that all of Ensign Group’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKEnsign Group, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKEnsign Group’s own Policies and Procedures; d. the personal obligations possible consequences to both Ensign Group and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith Ensign Group’s own Policies and Procedures, as well as the failure to report such noncompliance; e. the requirement that all of Ensign Group’s Covered Persons shall immediately report to the Compliance Officer, or other appropriate individual designated by Ensign Group, credible allegations of resident and/or patient harm and such report shall be complete, full, and honest; and e. f. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKEnsign Group’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already previously accomplished, within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Ensign Group’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Ensign Group shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.

Code of Conduct. Prior to the Effective DateCHSI has developed, GSK developed implemented and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered PersonsPersons and shall maintain this Code of Conduct for the duration of the CIA. GSK CHSI shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesTo the extent not already accomplished, or within 120 days after the Effective Date shall be revised to address Date, the followingCode of Conduct shall, at a minimum, set forth: a. GSKCHSI’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKCHSI’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKCHSI’s own Policies and Procedures; c. GSK’s the requirement that all of CHSI’s Covered Persons shall be expected to report to the Corporate Compliance and Privacy Officer, or other appropriate individual designated by GSKCHSI, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKCHSI’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKCHSI’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplishedCommunity Health Systems, within 120 days after the Effective Date, each Inc. Corporate Integrity Agreement CHSI currently requires all newly employed Covered Person shall certify, Persons to certify in writing or electronically, electronic form that he or she has received, read, understood, and shall abide by the CHSI’s Code of Conduct. CHSI shall maintain this practice for the duration of the CIA and shall ensure that New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after Person. CHSI shall distribute the Effective Date, whichever is laterCode of Conduct to all active medical staff members as described above and shall use its best efforts to encourage such active medical staff members to submit the required certification. GSK The Corporate Compliance and Privacy Officer shall maintain records indicating that the Code of Conduct was distributed to all active medical staff members and whether the certification was completed. CHSI shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.

Code of Conduct. Prior to To the Effective Dateextent not already completed, GSK developed and implemented a written Code of Conduct. Within 120 within 90 days after the Effective Date, GSK RMC shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK RMC shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKRMC’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKRMC’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKRMC’s own Policies and Procedures; c. GSK’s the requirement that all of RMC’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKRMC, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKRMC’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKRMC’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the RMC’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK RMC shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to To the Effective Dateextent not already accomplished, GSK developed and implemented a written Code of Conduct. Within 120 within 90 days after the Effective Date, GSK KDMC shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK KDMC shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKKDMC’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKKDMC’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKKDMC’s own Policies and Procedures; c. GSK’s the requirement that all of KDMC’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKKDMC, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKKDMC’s own Policies and Procedures; d. the personal obligations possible consequences to both KDMC and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith KDMC’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.G, and GSKKDMC’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the KDMC’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Additionally, the following shall constitute the obligations of KDMC under this Section III.B.1 with respect to physicians who have active medical staff membership but with whom KDMC does not have a financial relationship (“Excepted Physicians”): (i) KDMC shall make available or distribute the Code of Conduct to Excepted Physicians in accordance with the time requirements for other Covered Persons as set forth in this Section III.B.1; (ii) KDMC shall also use its best efforts to obtain written or electronic certification from each Excepted Physician indicating that he or she has received, read, understood, and shall abide by KDMC’s Code of Conduct; and (iii) KDMC shall keep records of the percentage of Excepted Physicians, and the names of Excepted Physicians, who have completed the certification requirement. KDMC shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. The Code of Conduct shall be distributed at least annually to all Covered Persons. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 60 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed Parkland adopted a Code of Conduct and implemented a written Ethics (Code of Conduct). Within 120 To the extent not already accomplished, within 90 days after the Effective Date, GSK Parkland shall revise, implement, and distribute the written Code of Conduct to all Covered Persons. GSK Parkland shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKParkland’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKParkland’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKParkland’s own Policies and Procedures; c. GSK’s the requirement that all of Parkland’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKParkland, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKParkland’s own Policies and Procedures; d. the personal obligations requirement that all of each Parkland’s Covered Person Persons shall immediately report to the Chief Quality and Safety Officer, or other appropriate individual designated by Parkland, credible allegations of patient harm and such report shall be complete, full, and honest; e. the possible consequences to both Parkland and Covered Persons of failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith Xxxxxxxx’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. f. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKParkland’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Datepromulgation of any revision to the Code of Conduct, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Xxxxxxxx’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Parkland shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalizedfinalized and approved by the Board. Each Covered Person shall certify, in writing or electronicallyelectronic form, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed King developed, implemented, and implemented distributed a written Code code of Conduct. Within 120 days after conduct known as the Effective Date, GSK shall distribute the written Corporate Code of Conduct and Ethics (the “Code”) to all Covered Persons. GSK King shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSK’s Xxxx’x commitment to full compliance with all Federal health care program requirements and FDA requirementsHealth Care Program Requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating government contracting and price reporting requirements, and to market, sell, promote, and advertise its products in accordance with Federal Health Care Program Requirements (including but not limited to, the Covered FunctionsFederal anti-kickback Sxxxxxx, xxxxxxxx xx 00 X.X.X. § 0000x-0x); b. GSK’s Xxxx’x requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, Health Care Program Requirements and with GSKKing’s own Policies and ProceduresProcedures as implemented pursuant to this Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of King’s Covered Persons shall be expected to report to the Compliance Officer, Officer or other appropriate individual designated by GSK, King suspected violations of any Federal health care program requirements, FDA requirements, Health Care Program Requirements or of GSKKing’s own Policies and Procedures; d. the personal obligations possible consequences to both King and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, Health Care Program Requirements and GSKwith King’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKKing’s commitment to nonretaliation Corporate Integrity Agreement King Pharmaceuticals, Inc. and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Code of ConductKing’s Code. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK King shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementCode.

Code of Conduct. Prior to the Effective Date, GSK Biovail developed and implemented a written Code program to distribute a code of conduct (known as its “Standards of Business Conduct”) to its employees, officers, and directors. Within 120 days after the Effective Date, GSK Biovail shall either amend its Standards of Business Conduct to meet the requirements set forth below, or Biovail shall develop, implement, and distribute the to all Covered Persons a written U.S. Healthcare Code of Conduct which meets the requirements set forth below. (For purposes of this CIA, the revised Standards of Business Conduct or the U.S. Healthcare Code, as applicable, shall be referred to all Covered Persons. GSK as the “Code of Conduct”.) Biovail shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKBiovail’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply market, sell, promote, research, develop, provide information about, and advertise its products in accordance with all requirements relating to the Covered FunctionsFederal health care program and FDA requirements; b. GSKBiovail’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, and FDA Requirements, requirements and with GSKBiovail’s own Policies and ProceduresProcedures as implemented pursuant to Section III.C (including the requirements of this CIA); c. GSK’s the requirement that all of Biovail’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKBiovail, suspected violations of any Federal health care program requirements, or FDA requirements, requirements or of GSKBiovaiI’s own Policies and Procedures; d. the personal obligations possible consequences to both Biovail and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, and FDA requirements, requirements and GSKwith Biovail’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKBiovail’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 150 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Biovail’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 150 days after the Effective Date, whichever is later. GSK Biovail shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalizedfinalized and approved by Biovail’s Board or Directors or a committee thereof. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective DateDate of this CIA, GSK developed CVS developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK CVS shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesConduct, or within 120 days after the Effective Date at a minimum, shall be revised continue to address the followingset forth: a. GSKCVS’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKCVS’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKCVS’s own Policies and Procedures;Procedures as implemented pursuant to this Section III.B (including the requirements of this CIA); CVS Caremark Corporate Integrity Agreement c. GSK’s the requirement that all of CVS’s Covered Persons shall be expected to report to the Compliance Officer, Officer or other appropriate individual designated by GSK, CVS suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKCVS’s own Policies and Procedures; d. the personal obligations possible consequences to both CVS and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith CVS’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKCVS’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each Each Covered Person shall certifyhas certified, in writing or electronically, that he or she has received, read, understood, and shall abide by the CVS’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK CVS shall continue to periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any To the extent CVS makes any material changes to the Code of Conduct, a revised Code of Conduct shall be distributed and made available to Covered Persons within 30 60 days after any revisions such changes are finalized. Each made and each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 90 days after the Effective Date, GSK Vanguard shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK Vanguard shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKVanguard’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSKVanguard’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKVanguard’s own Policies and Procedures; c. GSK’s the requirement that all of Vanguard’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKVanguard, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKVanguard’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKVanguard’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Vanguard’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Vanguard shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective DateDate of this CIA, GSK developed PharMerica adopted and implemented a written Code of Conduct. Within 120 days after distributed the Effective Date, GSK shall distribute the written Code of Conduct to all Covered PersonsPersons who are employees and the personnel file of each Covered Person who is an employee contains a written certification that he or she has received, read, understood, and shall abide by the Code of Conduct. GSK PharMerica shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includes, or within 120 days after the Effective Date shall be revised to address the followingreflects: a. GSK’s a commitment to full compliance with all federal, state and local laws and regulations (which includes Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions); b. GSK’s the requirement that all of its Covered Persons PharMerica’s officers, directors, and employees shall be expected to comply with all applicable federal, state and local laws and regulations (which includes Federal health care program requirements, FDA Requirements, and with GSK’s own Policies and Procedures); c. GSK’s the requirement that all Covered Persons of PharMerica’s officers and employees shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKPharMerica, suspected violations of the Code of Conduct or any Federal, state and local laws and regulations (which includes Federal health care program requirements, FDA requirements, or of GSK’s own Policies and Procedures); d. the personal obligations possible consequences to both PharMerica and individuals of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSK’s Policies and Proceduresthe failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKPharMerica’s commitment to nonretaliation non- retaliation . Covered Persons who are not employees and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Code of Conduct. New new Covered Persons shall receive the Code of Conduct and shall complete the required form of certification currently used for Covered Persons who are employees within the later of 120 days after the Effective Date or 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is laterPerson. GSK PharMerica shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 60 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 90 days after the Effective Date, GSK Rural/Metro Ohio shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK Rural/Metro Ohio shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKRural/Metro Ohio’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKRural/Metro Ohio’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKRural/Metro Ohio’s own Policies and Procedures; c. GSK’s the requirement that all of Rural/Metro Ohio’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKRural/Metro Ohio, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKRural/Metro Ohio’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKRural/Metro Ohio’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Rural/Metro Ohio’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Rural/Metro Ohio shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 days after the Effective Date, GSK Spectranetics shall develop, implement, and distribute the a revised written Code of Conduct to all Covered Persons. GSK Spectranetics shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSK’s Spectranetics’ commitment to full compliance with all FDA and Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSK’s Spectranetics’ requirement that all of its Covered Persons shall be expected to comply with all applicable FDA and all Federal health care program requirements, FDA Requirements, requirements and with GSK’s Spectranetics’ own Policies and ProceduresProcedures as implemented pursuant to Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of Spectranetics’ Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKSpectranetics, suspected violations of any FDA or Federal health care program requirements, FDA requirements, requirements or of GSK’s Spectranetics’ own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSK’s Spectranetics’ commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within Spectranetics Corporate Integrity Agreement Within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Spectranetics’ Code of Conduct. Spectranetics shall maintain documentation of such certification. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Spectranetics shall maintain documentation of the Code of Conduct certifications consistent with section VIII of the CIA. Spectranetics shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior Under the direction of the HCA Office of Compliance, a Code of 31 Conduct for adherence by all HCA employees and contract providers has been developed. 32 1. Within thirty (30) calendar days of award of this Agreement, HOSPITAL has the option of 33 submitting to ADMINISTRATOR a signed acknowledgement and agreement that HOSPITAL shall 34 comply with the Effective Date, GSK developed and implemented a written “HCA Contractor Code of Conduct. Within 120 days after the Effective Date, GSK ” specified in subparagraph B.3 below or HOSPITAL 35 shall distribute the written submit a copy of its Code of Conduct to all Covered PersonsADMINISTRATOR for review and comparison to federal, 36 state, and COUNTY standards by the HCA Compliance Officer. GSK shall make adherence 37 // 1 2. If HOSPITAL elects to the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includes, or within 120 days after the Effective Date shall be revised to address the following: a. GSK’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSK’s requirement that all submit a copy of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, and with GSK’s own Policies and Procedures; c. GSK’s requirement that all Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSK, suspected violations of any Federal health care program requirements, FDA requirements, or of GSK’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSK’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Code of Conduct. New Covered Persons , HCA’s Compliance Officer 2 shall receive the Code advise HOSPITAL of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK shall periodically review the any necessary changes to Hospital’s Code of Conduct to determine meet minimum 3 standards and HOSPITAL shall either take necessary action to meet said standards or shall be asked to 4 acknowledge and agree to the “HCA Contractor Code of Conduct” specified in subparagraph B.3. below. 5 3. HCA CONTRACTOR CODE OF CONDUCT – HOSPITAL and its employees and 6 subcontractors shall: 7 a. Comply with all applicable laws, regulations, rules or guidelines when providing and 8 billing for services specified herein. 9 b. Use their best efforts to conduct themselves honestly fairly, courteously and with a high 10 degree of integrity in their professional dealings related to this Agreement and avoid any conduct that 11 could reasonably be expected to reflect adversely upon the integrity of HOSPITAL and/or COUNTY. 12 c. Treat COUNTY employees, clients and other COUNTY contractors fairly and with 13 respect. 14 d. NOT engage in any activity in violation of this Agreement, nor engage in any other 15 conduct which violates any applicable law, regulation, rule or guideline. 16 e. Take precautions to ensure that claims are prepared and submitted accurately, timely and 17 are consistent with all applicable laws, regulations, rules or guidelines. 18 f. Ensure that no false, fraudulent, inaccurate or fictitious claims for payment or 19 reimbursement of any kind are submitted. 20 g. Xxxx only for eligible services actually rendered and fully documented and use billing 21 codes that accurately describe the services provided. 22 h. Act promptly to investigate and correct problems if revisions errors in claims or xxxxxxxx are appropriate and shall make 23 discovered. 24 i. Promptly report to HCA’S Compliance Officer any necessary revisions based on such reviewactivity that HOSPITAL believes 25 may violate the standards of the HCA Compliance Program, or any other applicable law, regulation, rule 26 or guideline. 27 j. Promptly report to HCA’S Compliance Officer any suspected violation(s) of this HCA 28 Contractor Code of Conduct by COUNTY employees. 29 k. Consult with HCA’s Compliance Officer if there are any questions or uncertainties of any 30 Compliance Program standard or any other applicable law regulation, rule or guideline. 31 4. Any revised Failure of HOSPITAL to submit the acknowledgement of the HCA Contractor Code of 32 Conduct or its own Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronically, that he or she has received, read, understoodconstitute a material breach of this Agreement, and failure to 33 cure such breach within sixty (60) calendar days of such notice from ADMINISTRATOR shall abide by constitute 34 grounds for termination of this Agreement as to the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreementnon-complying party.

Code of Conduct. Prior to the Effective Date, GSK developed DaVita developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct for DaVita Dialysis to all Covered Persons. GSK During the CIA Period, DaVita Dialysis shall make adherence to the performance of job responsibilities in a manner consistent with the Code of Conduct an element in evaluating the performance of all employees who are employed Covered PersonsPersons and shall implement a policy requiring that all contracted Covered Persons perform job responsibilities in a manner consistent with the Code of Conduct. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKDaVita’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSKDaVita’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKDaVita’s own Policies and Procedures; c. GSK’s the requirement that all of DaVita’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKDaVita, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKDaVita’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.L, and GSKDaVita’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the DaVita Dialysis’s Code of Conduct. New Covered Persons shall receive the Code of Conduct in hard copy or electronic form and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK DaVita shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each in hard copy or electronic form at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented PolyMedica presently has a written Code of Conduct. Within PolyMedica shall maintain a written Code of Conduct during the term of the CIA. To the extent not already accomplished, within 120 days after the Effective Date, GSK PolyMedica shall distribute the its written Code of Conduct to all Covered Persons. GSK PolyMedica shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSK’s PolyMedica's commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSK’s PolyMedica's requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSK’s PolyMedica's own Policies and ProceduresProcedures as implemented pursuant to this Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of PolyMedica's Covered Persons shall be expected to report to the Compliance Officer, Officer or other POLYMEDICA CORPORATE INTEGRITY AGREEMENT appropriate individual designated by GSK, PolyMedica suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSK’s PolyMedica's own Policies and Procedures; d. the personal obligations possible consequences to both PolyMedica and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSK’s with PolyMedica's own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSK’s PolyMedica's commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the PolyMedica's Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK To the extent a Covered Person is on a leave of absence, such Covered Person shall receive the Code of Conduct and complete the required certification within 30 days after the conclusion of the leave of absence. PolyMedica shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior Under the direction of the HCA Office of Compliance, a Code of 32 Conduct for adherence by all HCA employees and contract providers has been developed. 33 1. Within thirty (30) calendar days of award of this Agreement, HOSPITAL has the option of 34 submitting to ADMINISTRATOR a signed acknowledgement and agreement that HOSPITAL shall 35 comply with the Effective Date, GSK developed and implemented a written “HCA Contractor Code of Conduct. Within 120 days after the Effective Date, GSK ” specified in subparagraph B.3 below or Hospital 36 shall distribute the written submit a copy of its Code of Conduct to all Covered PersonsADMINISTRATOR for review and comparison to federal, 37 state, and COUNTY standards by the HCA Compliance Officer. 1 2. GSK shall make adherence If HOSPITAL elects to the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includes, or within 120 days after the Effective Date shall be revised to address the following: a. GSK’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSK’s requirement that all submit a copy of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, and with GSK’s own Policies and Procedures; c. GSK’s requirement that all Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSK, suspected violations of any Federal health care program requirements, FDA requirements, or of GSK’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSK’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Code of Conduct. New Covered Persons , HCA’S Compliance Officer 2 shall receive the Code advise HOSPITAL of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK shall periodically review the any necessary changes to Hospital’s Code of Conduct to determine meet minimum 3 standards and HOSPITAL shall either take necessary action to meet said standards or shall be asked to 4 acknowledge and agree to the “HCA Contractor Code of Conduct” specified in subparagraph B.3. below. 5 3. HCA CONTRACTOR CODE OF CONDUCT – HOSPITAL and its employees and 6 subcontractors shall: 7 a. Comply with all applicable laws, regulations, rules or guidelines when providing and 8 billing for services specified herein. 9 b. Use their best efforts to conduct themselves honestly fairly, courteously and with a high 10 degree of integrity in their professional dealings related to this Agreement and avoid any conduct that 11 could reasonably be expected to reflect adversely upon the integrity of HOSPITAL and/or COUNTY. 12 c. Treat COUNTY employees, clients and other COUNTY contractors fairly and with 13 respect. 14 d. NOT engage in any activity in violation of HCA’S Compliance Program, nor engage in 15 any other conduct which violates any applicable law, regulation, rule or guideline. 16 e. Take precautions to ensure that claims are prepared and submitted accurately, timely and 17 are consistent with all applicable laws, regulations, rules or guidelines. 18 f. Ensure that no false, fraudulent, inaccurate or fictitious claims for payment or 19 reimbursement of any kind are submitted. 20 g. Xxxx only for eligible services actually rendered and fully documented and use billing 21 codes that accurately describe the services provided. 22 h. Act promptly to investigate and correct problems if revisions errors in claims or xxxxxxxx are appropriate and shall make 23 discovered. 24 i. Promptly report to HCA’S Compliance Officer any necessary revisions based on such reviewactivity that HOSPITAL believes 25 may violate the standards of the HCA Compliance Program, or any other applicable law, regulation, rule 26 or guideline. 27 j. Promptly report to HCA’S Compliance Officer any suspected violation(s) of this HCA 28 Contractor Code of Conduct by COUNTY employees. 29 k. Consult with HCA’S Compliance Officer if there are any questions or uncertainties of 30 any Compliance Program standard or any other applicable law regulation, rule or guideline. 31 4. Any revised Failure of HOSPITAL to timely submit the acknowledgement of the HCA Contractor Code 32 of Conduct or its own Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronically, that he or she has received, read, understoodconstitute a material breach of this Agreement, and failure to 33 cure such breach within sixty (60) calendar days of such notice from ADMINISTRATOR shall abide by constitute 34 grounds for termination of this Agreement as to the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreementnon-complying party.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a Amedisys shall maintain its written Code “Standards of Conduct. Within 120 .” The “Standards of Conduct” shall be distributed to any Covered Persons within 90 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK Amedisys shall make the promotion of, and adherence to to, the Code “Standards of Conduct Conduct” an element in evaluating the performance of all employees who are Covered Personsemployees. The Code “Standards of Conduct includesConduct” shall, or within 120 days after the Effective Date shall be revised to address the following:at a minimum, set forth: Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 3 a. GSK’s Amedisys’ commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSK’s Amedisys’ requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSK’s Amedisys’ own Policies and ProceduresProcedures as implemented pursuant to Section III.B.2 (including the requirements of this CIA); c. GSK’s the requirement that all of Amedisys’ Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKAmedisys, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSK’s Amedisys’ own Policies and Procedures; d. the personal obligations possible consequences to both Amedisys and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSK’s with Amedisys’ own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSK’s Amedisys’ commitment to nonretaliation and to maintainmaintain confidentiality, as appropriate, confidentiality and anonymity nonretaliation with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Code Amedisys’ “Standards of Conduct. .” New Covered Persons shall receive the Code “Standards of Conduct Conduct” and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Amedisys shall periodically review the Code “Standards of Conduct Conduct” to determine if revisions are appropriate and shall make any necessary revisions based on such a review. Any such revised Code of Conduct shall be distributed within 30 days after any revisions are finalizedfinalizing such changes. Each Covered Person shall certify, in writing or electronically, certify that he or she has received, read, Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 4 understood, and shall abide by the revised Code “Standards of Conduct Conduct” within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreementsuch revisions.

Code of Conduct. Prior to the Effective DateTxxxx has developed, GSK developed implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK During the term of the CIA, Txxxx shall maintain the Code of Conduct and make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSK’s Xxxxx’x commitment to full fall compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSK’s Xxxxx’x requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSK’s Txxxx’x own Policies and ProceduresProcedures as implemented pursuant to Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of Txxxx’x Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKTenet, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSK’s Txxxx’x own Policies and Procedures; d. the personal obligations possible consequences to both Txxxx and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSK’s with Txxxx’x own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSK’s Txxxx’x commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within Within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Txxxx’x Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Notwithstanding any provision in this section, Txxxx shall use best efforts to obtain written certifications from Excepted Physicians and shall keep records of the percentage of Excepted Physicians who have completed the certification. Txxxx shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed Cephalon developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK Cephalon currently requires all newly employed persons to certify in writing or electronically that they have received, read, understood, and shall abide by Cephalon’s Code of Conduct. Cephalon shall continue to make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includessets forth and shall continue to set forth, or within 120 days after the Effective Date shall be revised to address at a minimum, the following: a. GSKCephalon’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply market, sell, promote, research, develop, provide information about, and advertise its products in accordance with all Federal health program requirements relating to the Covered Functionsand FDA requirements; b. GSKCephalon’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, and FDA Requirements, requirements and with GSKCephalon’s own Policies and ProceduresProcedures as implemented pursuant to Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of Cephalon’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKCephalon, suspected violations of any Federal health care program requirements, and FDA requirements, requirements or of GSKCephalon’s own Policies and Procedures; d. the personal obligations possible consequences to both Cephalon and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, and FDA requirements, requirements and GSKwith Cephalon’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKCephalon’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, the Code of Conduct shall be distributed to each Covered Person and each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Cephalon’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Cephalon shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective DateBaptist has developed, GSK developed implemented and implemented distributed a written Code of ConductConduct to all Covered Persons, and shall maintain a Code of Conduct for the duration of the CIA. Within 120 days after the Effective Date, GSK Baptist shall distribute the written document its distribution of its Code of Conduct to all Covered Persons. GSK Baptist shall continue to make adherence to the performance of job responsibilities in a manner consistent with the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKBaptist’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKBaptist’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKBaptist’s own Policies and Procedures; c. GSK’s the requirement that all of Baptist’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKBaptist, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKBaptist’s own Policies and Procedures;; and, d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKXxxxxxx’s commitment to nonretaliation non- retaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within Within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has receivedreceived or accessed, read, understood, and shall abide by the Baptist’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Baptist shall distribute the Code of Conduct to all active medical staff members described herein and shall use its best efforts to encourage such active medical staff members to submit the required certification. The Compliance Officer shall maintain records indicating that the Code of Conduct was distributed to all active medical staff members and whether the certification was completed. Baptist shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.

Code of Conduct. Prior To the extent not completed prior to the Effective Date, GSK developed and implemented a written Code within 90 days of Conduct. Within 120 days after the Effective Date, GSK HealthSouth shall adopt and distribute the written a Code of Conduct to all Covered Persons. GSK HealthSouth shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKHealthSouth’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKHealthSouth’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKHealthSouth’s own Policies internal policies and Proceduresprocedures (including the requirements of this CIA); c. GSK’s the requirement that all of HealthSouth’s Covered Persons shall be expected to report to the Compliance Officer, Officer or other appropriate individual designated by GSK, HealthSouth suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKHealthSouth’s own Policies policies and Proceduresprocedures; d. the personal obligations possible consequences to both HealthSouth and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith HealthSouth’s Policies own policies and Proceduresprocedures and the failure to report such noncompliance; andand Corporate Integrity Agreement HealthSouth Corporation e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKHealthSouth’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, to the extent not already completed, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the HealthSouth’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK HealthSouth shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised revisions to the Code of Conduct shall be distributed communicated to Covered Persons and Covered Contractors within 30 days after the effective date of any revisions are finalizedrevisions. Each In the case of a significant change to the Code of Conduct, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 60 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementDistribution may include publishing the Code of Conduct on HealthSouth’s intranet or other internal web site available to all employees. If HealthSouth uses such an electronic method of distribution, it must notify the individuals receiving the Code of Conduct that the Code of Conduct will be distributed in such a manner and it must monitor the distribution to ensure that all appropriate individuals received the Code of Conduct.

Code of Conduct. Prior to the Effective Date, GSK developed Orthofix developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK Orthofix shall continue to make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKOrthofix’s commitment to full compliance with all Federal health care program requirements requirements, including its commitment to prepare and submit accurate claims and to contract and enter into Arrangements consistent with such requirements; b. Orthofix’s commitment to full compliance with all FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions;Promotional and Product Services Related Functions and to market, sell, promote, research, develop, provide information about, and advertise its products in accordance with Federal health program requirements and FDA requirements. b. GSKc. Orthofix’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, and FDA Requirements, requirements and with GSKOrthofix’s own Policies and ProceduresProcedures as implemented pursuant to Section III.B.2; c. GSK’s d. the requirement that all of Orthofix’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKOrthofix, suspected violations of any Federal health care program requirements, requirements or FDA requirements, requirements or of GSKOrthofix’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKXxxxxxxx’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, Xxxxxxxx’s Code of Conduct shall be distributed to each Covered Person and each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Xxxxxxxx’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Orthofix shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 90 days after the Effective Date, GSK AtriCure, Inc. shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK AtriCure, Inc. shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKAtriCure, Inc.’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply market, sell, promote, research, develop, provide information about, and advertise its products in accordance with all Federal health care program and FDA requirements relating and to the Covered Functionsprepare and submit accurate claims consistent with such requirements; b. GSKAtriCure, Inc.’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, and FDA Requirements, requirements and with GSKAtriCure, Inc.’s own Policies and Procedures; c. GSK’s the requirement that all of AtriCure, Inc.’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKAtriCure, Inc., suspected violations of any Federal health care program requirementsand FDA requirements and of AtriCure, FDA requirements, or of GSKInc.’s own Policies and Procedures;; and CORPORATE INTEGRITY AGREEMENT ATRICURE, INC. d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKAtriCure, Inc.’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the AtriCure, Inc.’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK AtriCure, Inc. shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed WellCare developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK WellCare shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesTo the extent not already accomplished, or within 120 90 days after the Effective Date Date, WellCare shall be revised to address ensure that the followingCode of Conduct shall, at a minimum, set forth: a. GSK’s WellCare's commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSK’s WellCare's requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSK’s WellCare's own Policies and Procedures; c. GSK’s the requirement that all of WellCare's Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual individuals designated by GSKWellCare, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSK’s WellCare's own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSK’s WellCare's commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the WellCare's Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Covered Persons Corporate Integrity Agreement WellCare Health Plans, Inc. who had made the required certification within 60 days prior to the Effective Date are not required to recertify. WellCare shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK Hill-Rom developed and implemented a written Code of Conduct. Within 120 days after the Effective Date, GSK Hill-Rom shall distribute the its written Code of Conduct to all Covered Persons. GSK Persons and shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKx. Xxxx-Rom’s commitment to full compliance with any and all applicable Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKx. Xxxx-Rom’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKHill-Rom’s own Policies and Procedures; c. GSK’s the requirement that all of Hill-Rom’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKHill-Rom, suspected violations of any applicable Federal health care program requirements, FDA requirements, requirements or of GSKHill-Rom’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKHill-Rom’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within Within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Hill-Rom’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 60 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Hill-Rom shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any To the extent that Hill-Rom makes material revisions to the Code of Conduct, the revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 90 days after the Effective Date, GSK the DIG Entities shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK The DIG Entities shall make adherence to the performance of job responsibilities in a manner consistent with the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSK’s the DIG Entities’ commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSK’s the DIG Entities’ requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSK’s the DIG Entities’ own Policies and Procedures; c. GSK’s the requirement that all of the DIG Entities’ Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKthe DIG Entities, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSK’s the DIG Entities’ own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.F, and GSK’s the DIG Entities’ commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the DIG Entities’ Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK The DIG Entities shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.

Code of Conduct. Prior to To the Effective Dateextent not already accomplished, GSK developed and implemented a written Code of Conduct. Within 120 within 90 days after the Effective Date, GSK Daiichi shall update, implement, and distribute the a written Code of Conduct that meets the requirements of this paragraph III.B.1 to all Covered Persons. GSK Daiichi shall make adherence to the performance of job responsibilities in a manner consistent with the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includesshall include, or within 120 days after the Effective Date shall be revised to address at a minimum, the following: a. GSKDaiichi’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSKDaiichi’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements and FDA requirements, FDA Requirements, and with GSKDaiichi’s own Policies and Procedures; c. GSKDaiichi’s requirement that all Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKDaiichi, suspected violations of any Federal health care program requirements, FDA requirements, or of GSKDaiichi’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKDaiichi’s commitment to nonretaliation non- retaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Daiichi’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Daiichi shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.

Code of Conduct. Prior to the Effective DateCHSI has developed, GSK developed implemented and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered PersonsPersons and shall maintain this Code of Conduct for the duration of the CIA. GSK CHSI shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesTo the extent not already accomplished, or within 120 days after the Effective Date shall be revised to address Date, the followingCode of Conduct shall, at a minimum, set forth: a. GSKCHSI’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC commitment to prepare and submit accurate claims consistent with such requirements; Community Health Systems, Inc. Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions;Agreement, Amended b. GSKCHSI’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKCHSI’s own Policies and Procedures; c. GSK’s the requirement that all of CHSI’s Covered Persons shall be expected to report to the Corporate Compliance and Privacy Officer, or other appropriate individual designated by GSKCHSI, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKCHSI’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKCHSI’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each CHSI currently requires all newly employed Covered Person shall certify, Persons to certify in writing or electronically, electronic form that he or she has received, read, understood, and shall abide by the CHSI’s Code of Conduct. CHSI shall maintain this practice for the duration of the CIA and shall ensure that New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after Person. CHSI shall distribute the Effective Date, whichever is laterCode of Conduct to all active medical staff members as described above and shall use its best efforts to encourage such active medical staff members to submit the required certification. GSK The Corporate Compliance and Privacy Officer shall maintain records indicating that the Code of Conduct was distributed to all active medical staff members and whether the certification was completed. CHSI shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.

Code of Conduct. Prior to the Effective Date, GSK developed BIPI developed, implemented, and implemented distributed a written code of conduct to all Covered Persons who are BIPI employees. This code is known as BIPI’s Code of Conduct and Corporate Integrity (Code of Conduct). Within 120 days after the Effective DateXXXX makes, GSK and shall distribute the written Code of Conduct continue to all Covered Persons. GSK shall make make, adherence to the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includes, or within 120 90 days after the Effective Date Date, shall be revised to address or include the following: a. GSKBIPI’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSKBIPI’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, and with GSKBIPI’s own Policies and Procedures; c. GSKBIPI’s requirement that all Covered Persons shall be expected to report to the Compliance OfficerCECO, or other appropriate individual designated by GSKBIPI, suspected violations of any Federal health care program requirements, FDA requirements, or of GSKBIPI’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSKBIPI’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKXXXX’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each Covered Person shall certify, either in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the XXXX’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK BIPI shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective DatePRMC has developed, GSK developed implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK During the term of the CIA, PRMC shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKPRMC’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKPRMC’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, and with GSKPRMC’s own Policies and ProceduresProcedures as implemented pursuant to Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of PRMC’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKPRMC, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKPRMC’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKPRMC’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the PRMC’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK PRMC shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior Under the direction of the HCA Office of Compliance, a Code of 34 Conduct for adherence by all HCA employees and contract providers has been developed. 35 1. Within thirty (30) calendar days of award of this Agreement, HOSPITAL has the option of 36 submitting to ADMINISTRATOR a signed acknowledgement and agreement that HOSPITAL shall 37 comply with the Effective Date, GSK developed and implemented a written “HCA Contractor Code of Conduct. Within 120 days after the Effective Date, GSK ” specified in subparagraph B.3 below or Hospital 1 shall distribute the written submit a copy of its Code of Conduct to all Covered PersonsADMINISTRATOR for review and comparison to federal, 2 state, and COUNTY standards by the HCA Compliance Officer. 3 2. GSK shall make adherence If HOSPITAL elects to the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includes, or within 120 days after the Effective Date shall be revised to address the following: a. GSK’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSK’s requirement that all submit a copy of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, and with GSK’s own Policies and Procedures; c. GSK’s requirement that all Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSK, suspected violations of any Federal health care program requirements, FDA requirements, or of GSK’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSK’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Code of Conduct. New Covered Persons , HCA’s Compliance Officer 4 shall receive the Code advise HOSPITAL of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK shall periodically review the any necessary changes to Hospital’s Code of Conduct to determine meet minimum 5 // 6 standards and HOSPITAL shall either take necessary action to meet said standards or shall be asked to 7 acknowledge and agree to the “HCA Contractor Code of Conduct” specified in subparagraph B.3. below. 8 3. HCA CONTRACTOR CODE OF CONDUCT – HOSPITAL and its employees and 9 subcontractors shall: 10 a. Comply with all applicable laws, regulations, rules or guidelines when providing and 11 billing for services specified herein. 12 b. ConductUse their best efforts to conduct themselves honestly fairly, courteously and with 13 a high degree of integrity in their professional dealings related to this Agreement and avoid any conduct 14 that could reasonably be expected to reflect adversely upon the integrity of HOSPITAL and/or COUNTY. 15 c. Treat COUNTY employees, clients and other COUNTY contractors fairly and with 16 respect. 17 d. NOT engage in any activity in violation of HCA’S Compliance Program, nor engage in 18 any other conduct which violates any applicable law, regulation, rule or guideline. 19 e. Take precautions to ensure that claims are prepared and submitted accurately, timely and 20 are consistent with all applicable laws, regulations, rules or guidelines. 21 f. Ensure that no false, fraudulent, inaccurate or fictitious claims for payment or 22 reimbursement of any kind are submitted. 23 g. Xxxx only for eligible services actually rendered and fully documented and use billing 24 codes that accurately describe the services provided. 25 h. Act promptly to investigate and correct problems if revisions errors in claims or xxxxxxxx are appropriate and shall make 26 discovered. 27 i. Promptly report to HCA’S Compliance Officer any necessary revisions based on such reviewactivity that HOSPITAL believes 28 may violate the standards of the HCA Compliance Program, or any other applicable law, regulation, rule 29 or guideline. 30 j. Promptly report to HCA’S Compliance Officer any suspected violation(s) of this HCA 31 Contractor Code of Conduct by COUNTY employees. 32 k. Consult with HCA’s Compliance Officer if there are any questions or uncertainties of 33 any Compliance Program standard or any other applicable law regulation, rule or guideline. 34 4. Any revised Failure of HOSPITAL to timely submit the acknowledgement of the HCA Contractor Code 35 of Conduct or its own Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronically, that he or she has received, read, understoodconstitute a material breach of this Agreement, and failure to 36 cure such breach within sixty (60) calendar days of such notice from ADMINISTRATOR shall abide by constitute 37 grounds for termination of this Agreement as to the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreementnon-complying party.

Code of Conduct. Prior Zimmer represented to the OIG that, prior to the Effective DateDate of this CIA, GSK Zimmer developed and implemented a written Code of Business Conduct (“the Code of Conduct”). Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK Zimmer shall make the promotion of, and adherence to to, the Code of Business Conduct (“Code of Conduct”) an element in evaluating the performance of all employees who are Covered Personsemployees. The To the extent not already addressed in the Code of Conduct, within 90 days of the Effective Date, the Code of Conduct includes, or within 120 days after the Effective Date shall be revised to address include, at a minimum, the followingfollowing elements: a. GSK’s Xxxxxx’x commitment to full compliance with all federal, state and Corporate Integrity Agreement between OIG-HHS and Zxxxxx, Inc. local laws and regulations (which includes Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions); b. GSK’s Xxxxxx’x requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSK’s Zxxxxx’x own Policies and ProceduresProcedures as implemented pursuant to this Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all Covered Persons shall be expected to report to the their Compliance Officer, or other appropriate individual individuals designated by GSKZimmer, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSK’s Zxxxxx’x own Policies and Procedures; d. the personal obligations possible consequences to Zimmer and Covered Persons of each Covered Person failure to comply with all Federal health care program requirements, FDA requirements, requirements and GSK’s with Zxxxxx’x Policies and ProceduresProcedures and the failure to report such non-compliance; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSK’s Zxxxxx’x commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, Zimmer shall distribute the Code of Conduct (revised as necessary to include the elements set forth above) to each Covered Person shall and each Covered Person will certify, in writing or electronically, that he or she has received, read, understood, understood and shall abide by Zxxxxx’x Code of Conduct. Zimmer may distribute the Code of ConductConduct and the required certification to each Covered Person either electronically or in hard-copy form. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Zimmer shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronically, that he or she Corporate Integrity Agreement between OIG-HHS and Zxxxxx, Inc. has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Dateexecution of this CIA, GSK developed and implemented Tender Loving Care established a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct that as represented to the OIG, meets the requirements of this Section III.B. 1. To the extent not already accomplished, the Code of Conduct shall be distributed to all Covered PersonsPersons within 120 days of the effective date of this CIA. GSK Tender Loving Care shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address at a minimum, set forth the following: a. GSK’s Tender Loving Care's commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims for reimbursement consistent with all requirements relating to the Covered Functionssuch requirements; b. GSK’s Tender Loving Care's requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSK’s Tender Loving Care's own Policies and ProceduresProcedures as implemented pursuant to section 111.B (including the requirements of this CIA); c. GSK’s the requirement that all of Tender Loving Care's Covered Persons shall be expected to report to the Compliance Officer, Officer or other appropriate individual designated by GSK, Tender Loving Care any suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSK’s Tender Loving Care's own Policies and Procedures; d. the personal obligations possible consequences to both Tender Loving Care and Covered Persons of each Covered Person failure to comply with all Federal health care program requirements, FDA requirements, requirements and GSK’s with Tender Loving Care's own Policies and ProceduresProcedures or of failure to report such non-compliance; and e. the right of all individuals to use the Confidential Disclosure Program as described in Section III.Fsection III.E, and GSK’s Tender Loving Care's commitment to nonretaliation and to maintainmaintain confidentiality, as appropriate, confidentiality and anonymity non-retaliation with respect to such disclosures. To the extent not already accomplished, within 120 days after of the Effective Dateeffective date of the CIA, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall will abide by the Tender Loving Care's Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days two weeks after becoming a Covered Person or within 120 days after of the Effective Dateeffective date of the CIA, whichever is later. GSK Tender Loving Care shall periodically annually review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such a review. Any revised significant changes in the Code of Conduct shall be distributed within 30 days after any revisions are finalizedof finalizing such changes. Each Covered Person Persons shall certify, in writing or electronically, certify that he or she has they have received, read, understood, understood and shall will abide by the revised Code of Conduct within 30 days after of the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreementsuch revisions.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 90 days after the Effective Date, GSK Exactech shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK Exactech shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall at a minimum, or within 120 days after set forth the Effective Date shall be revised to address the followingfollowing elements: a. GSKExactech’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSKExactech’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKExactech’s own Policies and Procedures; c. GSK’s the requirement that all of Exactech’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKExactech, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKExactech’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKExactech’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Exactech’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Exactech shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to GGNSC has and shall maintain for the Effective Date, GSK developed and implemented term of the CIA a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct that is distributed to all Covered Persons. GSK GGNSC shall continue to make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKGGNSC’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKGGNSC’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKGGNSC’s own Policies and ProceduresProcedures as implemented pursuant to Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of GGNSC’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKGGNSC, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKGGNSC’s own Policies and Procedures; d. the personal obligations requirement that all of each GGNSC’s Covered Person Persons shall immediately report to the Chief Compliance Officer, or other appropriate individual designated by GGNSC, credible allegations of resident harm and such report shall be complete, full, and honest; e. the possible consequences to both GGNSC and Covered Persons of failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith GGNSC’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. f. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKGGNSC’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the GGNSC’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK GGNSC shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to To the Effective Dateextent not already accomplished, GSK developed and implemented a written Code of Conduct. Within within 120 days after the Effective Date, GSK Medco shall distribute the a written Code of Conduct to all Covered Persons. GSK Medco shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees. Distribution may include publishing the Code of Conduct on Medco’s intranet or other internal web site available to all of its employees who are and Covered Persons. If Medco uses such an electronic distribution method, it must notify the individuals of the distribution of the Code of Conduct in that manner and it must monitor the distribution to ensure that all appropriate individuals receive the revised Code of Conduct. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKMedco’s commitment to full compliance with all Covered Federal health care program requirements and FDA Program requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functions;such requirements; Medco CIA b. GSKMedco’s requirement that all of its Covered Persons shall be expected to comply with all applicable Covered Federal health care program requirements, FDA Requirements, Program requirements and with GSKMedco’s own Policies and ProceduresProcedures as implemented pursuant to this Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of Medco’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKMedco, suspected violations of any Covered Federal health care program requirements, FDA requirements, Program requirements or of GSKMedco’s own Policies and Procedures; d. the personal obligations possible consequences to both Medco and Covered Persons of each Covered Person failure to comply with Covered Federal health care program requirements, FDA requirements, Program requirements and GSKwith Medco’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKMedco’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosuresdisclosures made under the Disclosure Program. To the extent not already accomplished, within Within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Medco’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Medco shall make available to each Covered Contractor, either through a contract attachment, posting on its web site or by other reasonable means, a copy of Medco’s Code of Conduct, and shall confirm that the Covered Contractor has its own comparable compliance program. Medco shall request that the Covered Contractor make available a copy of the Medco Code of Conduct to its employees and/or agents who it believes are reasonably expected to provide Covered Contractor services to Medco for more than 160 hours each calendar year. Medco CIA Medco shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any materially revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each In the case of a material change to the Code of Conduct, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the materially revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK Hill-Rom developed and implemented a written Code of Conduct. Within 120 days after the Effective Date, GSK Hill-Rom shall distribute the its written Code of Conduct to all Covered Persons. GSK Persons and shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKx. Xxxx-Rom’s commitment to full compliance with any and all applicable Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKx. Xxxx-Rom’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKHill-Rom’s own Policies and Procedures;; Hill-Rom Corporate Integrity Agreement c. GSK’s the requirement that all of Hill-Rom’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKHill-Rom, suspected violations of any applicable Federal health care program requirements, FDA requirements, requirements or of GSKHill-Rom’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKHill-Rom’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within Within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Hill-Rom’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 60 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Hill-Rom shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any To the extent that Hill-Rom makes material revisions to the Code of Conduct, the revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective DateCHSI has developed, GSK developed implemented and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered PersonsPersons and shall maintain this Code of Conduct for the duration of the CIA. GSK CHSI shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesTo the extent not already accomplished, or within 120 days after the Effective Date shall be revised to address Date, the followingCode of Conduct shall, at a minimum, set forth: a. GSKCHSI’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC commitment to prepare and submit accurate claims consistent with such requirements; Community Health Systems, Inc. Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions;Agreement b. GSKCHSI’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKCHSI’s own Policies and Procedures; c. GSK’s the requirement that all of CHSI’s Covered Persons shall be expected to report to the Corporate Compliance and Privacy Officer, or other appropriate individual designated by GSKCHSI, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKCHSI’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKCHSI’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each CHSI currently requires all newly employed Covered Person shall certify, Persons to certify in writing or electronically, electronic form that he or she has received, read, understood, and shall abide by the CHSI’s Code of Conduct. CHSI shall maintain this practice for the duration of the CIA and shall ensure that New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after Person. CHSI shall distribute the Effective Date, whichever is laterCode of Conduct to all active medical staff members as described above and shall use its best efforts to encourage such active medical staff members to submit the required certification. GSK The Corporate Compliance and Privacy Officer shall maintain records indicating that the Code of Conduct was distributed to all active medical staff members and whether the certification was completed. CHSI shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.

Code of Conduct. Prior to the Effective Date, GSK developed EGS developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered PersonsPersons who are EGS officers and employees. GSK During the term of the CIA, EGS shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all officers and employees who are Covered Persons. The Code of Conduct includes, or within 120 60 days after the Effective Date Date, shall be revised to address or include the following: a. GSKEGS’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSKEGS’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirementsthe False Claims Act (codified at 31 U.S.C. §§ 3729-3733), and Federal anti-kickback statute (codified at 42 U.S.C. §§ 1320a-7b(b)), and with GSKEGS’s own Policies and Procedures; c. GSK’s the requirement that all of EGS’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKEGS, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKEGS’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.H, and GSKEGS’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the EGS’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK EGS shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 90 days after the Effective Date, GSK Xxxxxxx Lutheran shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK Xxxxxxx Lutheran shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKXxxxxxx Lutheran’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKXxxxxxx Lutheran’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKXxxxxxx Lutheran’s own Policies and Procedures; c. GSK’s d. the requirement that all of Xxxxxxx Lutheran’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKXxxxxxx Lutheran, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKXxxxxxx Lutheran’s own Policies and Procedures; d. e. the personal obligations requirement that all of each Xxxxxxx Lutheran’s Covered Person Persons shall immediately report to comply with Federal health care program requirementsthe Compliance Officer, FDA requirementsXxxxxxx Lutheran Corporate Integrity Agreement or other appropriate individual designated by Xxxxxxx Lutheran, credible allegations of resident harm and such report shall be complete, full, and GSK’s Policies and Procedureshonest; and e. f. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKXxxxxxx Lutheran’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Xxxxxxx Lutheran’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Xxxxxxx Lutheran shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed Novartis developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK Novartis shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSK’s Novartis’ commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply market, sell, promote, research, develop, provide information about, and advertise its products in accordance with all Federal health program requirements relating to the Covered Functionsand FDA requirements; b. GSK’s Novartis’ requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, and FDA Requirements, requirements and with GSK’s Novartis’ own Policies and Procedures; c. GSK’s the requirement that all of Novartis’ Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKNovartis, suspected violations of any Federal health care program requirements, or FDA requirements, requirements or of GSK’s Novartis’ own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSK’s Novartis’ commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplishedaccomplished within the last 150 days, within 120 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Novartis’ Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Novartis shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any Novartis Pharmaceuticals Corporation Corporate Integrity Agreement revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK Amedisys has developed and implemented a written Code of Conduct. Within 120 90 days after the Effective Date, GSK Amedisys shall distribute the written Code of Conduct to all Covered Persons. GSK Amedisys shall continue to make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKAmedisys’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKAmedisys’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKAmedisys’s own Policies and Procedures; c. GSK’s the requirement that all of Amedisys’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKAmedisys, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKAmedisys’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKAmedisys’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within Within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Amedisys’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Amedisys shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalizedat least annually to all Covered Persons. Each Covered Person shall certifyAmedisys, in writing or electronicallyInc. and Amedisys Holding, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement

Code of Conduct. Prior to Within 90 days after the Effective Suspension Termination Date, GSK developed and implemented a Maxim shall modify its existing written Code of Conduct. Within 120 days after the Effective Date, GSK shall Conduct and distribute the written and implement this revised Code of Conduct to all Covered Persons, if Maxim has not already done so after the Effective Date or within one month prior to the Effective Date. GSK Maxim shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKMaxim’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered FunctionsFederal health care program requirements; b. GSKMaxim’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKMaxim’s own Policies and Procedures; c. GSK’s the requirement that all of Maxim’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKMaxim, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKMaxim’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKMaxim’s commitment to nonretaliation non- retaliation and to maintainmaintaining, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Suspension Termination Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Maxim’s Code of Conduct, if each Covered Person has not already done so after the Effective Date or within one month prior to the Effective Date. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Suspension Termination Date, whichever is later. GSK Maxim shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective DatePediatrix certifies that it has developed, GSK developed implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK For the duration of this CIA, Pediatrix shall continue to maintain the Code of Conduct. Pediatrix shall amend the Code of Conduct, as necessary, to ensure that the Code of Conduct meets the requirements set forth below. In the event the Code of Conduct must be revised to meet the requirements set forth below, the revised Code of Conduct shall be made available to all Covered Persons within 120 days after the Effective Date. Pediatrix shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised at a minimum, continue to address the followingaddress: a. GSKPediatrix’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKPediatrix’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKPediatrix’s own Policies and ProceduresProcedures as implemented pursuant to Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of Pediatrix’s Covered Persons shall be expected to report to the Compliance Officer, Officer or other appropriate individual designated by GSK, Pediatrix suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKPediatrix’s own Policies and Procedures;; Pediatrix Medical Group, Inc. Corporate Integrity Agreement d. the personal obligations possible consequences to both Pediatrix and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith Pediatrix’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKPediatrix’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within Within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Pediatrix’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Pediatrix shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPediatrix shall have the option of distributing the Code of Conduct through electronic means (e.g., Company-wide e-mail or distribution through the Internet or Company’s Intranet site). Such electronic means of distribution shall include an electronic acknowledgement for Covered Persons to indicate that they have received, read, understood, and agree to abide by the Code of Conduct. If Pediatrix utilizes such electronic methods of distribution, it shall notify the Covered Persons that the Code of Conduct shall be distributed in such a manner and it shall track the distribution to ensure that all Covered Persons have received the Code of Conduct. Appropriate and knowledgeable staff shall be available to explain the Code of Conduct.

Code of Conduct. Prior to the Effective DateDate of this CIA, GSK developed Walgreens developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after , known as the Effective Date, GSK shall distribute the written Pharmacy Code of Conduct Conduct, to all Covered Persons. GSK To the extent that Walgreens conducts performance evaluations of Covered Persons, Walgreens shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are employees. To the extent that Covered PersonsPersons do not receive performance evaluations, Walgreens shall notify such Covered Persons that violations of the Code of Conduct may result in disciplinary action, including termination of employment. The Code of Conduct includesConduct, or within 120 days after the Effective Date at a minimum, shall be revised continue to address the followingset forth: a. GSKWalgreens’s commitment to full compliance with all applicable Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKWalgreens’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKWalgreens’s own Policies and ProceduresProcedures as implemented pursuant to this Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of Walgreens’s Covered Persons shall be expected to report to the Compliance Officer, Officer or other appropriate individual designated by GSK, Walgreens suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKWalgreens’s own Policies and Procedures; d. the personal obligations possible consequences to both Walgreens and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith Walgreens’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKWalgreens’s commitment to nonretaliation non- retaliation and to maintainmaintaining, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 150 days after the Effective Date, each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Walgreens’ Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 150 days after the Effective Date, whichever is later, unless the employment of such new Covered Person terminates in less than 30 days. GSK Walgreens shall continue to periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any To the extent Walgreens makes any material changes to the Code of Conduct, any revised Code of Conduct shall be distributed and made available to Covered Persons within 30 60 days after any such revisions are finalized. Each , and each Covered Person shall certify, in writing or electronicallyin electronic form, if applicable, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 45 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed Baxano Surgical developed, implemented, and implemented distributed a written code of conduct to all Covered Persons who are Baxano Surgical employees. This code is known as Baxano Surgical’s Code of Business Conduct and Ethics (Code of Conduct). Within 120 days after Baxano Surgical makes, and shall continue to make, the Effective Datepromotion of, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK shall make and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includes, or within 120 days after the Effective Date Date, shall be revised to address or include the following: a. GSKBaxano Surgical’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Promotional and Product Services Related Functions; b. GSKBaxano Surgical’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, and with GSKBaxano Surgical’s own Policies and Procedures; c. GSK’s the requirement that all of Baxano Surgical’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKBaxano Surgical, suspected violations of any Federal health care program requirements, FDA requirements, or of GSKBaxano Surgical’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSKBaxano Surgical’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKBaxano Surgical’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within Within 120 days after the Effective Date, each Covered Person shall certify, either in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Baxano Surgical’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Baxano Surgical shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective DateCHSI has developed, GSK developed and implemented anddistributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered PersonsPersons and shall maintain this Code of Conduct for the duration of the CIA. GSK CHSI shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesTo the extent not already accomplished, or within 120 days after the Effective Date shall be revised to address Date, the followingCode of Conduct shall, at a minimum, set forth: a. GSKCHSI’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKCHSI’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKCHSI’s own Policies and Procedures; c. GSK’s the requirement that all of CHSI’s Covered Persons shall be expected to report to the Corporate Compliance and Privacy Officer, or other appropriate individual designated by GSKCHSI, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKCHSI’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKCHSI’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, each CHSI currently requires all newly employed Covered Person shall certify, Persons to certify in writing or electronically, electronic form that he or she has received, read, understood, and shall abide by the CHSI’s Code of Conduct. CHSI shall maintain this practice for the duration of the CIA and shall ensure that New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after Person. CHSI shall distribute the Effective Date, whichever is laterCode of Conduct to all active medical staff members as described above and shall use its best efforts to encourage such active medical staff members to submit the required certification. GSK The Corporate Compliance and Privacy Officer shall maintain records indicating that the Code of Conduct was distributed to all active medical staff members and whether the certification was completed. CHSI shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.

Code of Conduct. Prior to the Effective Date, GSK developed Parkland adopted a Code of Conduct and implemented a written Ethics (Code of Conduct). Within 120 To the extent not already accomplished, within 90 days after the Effective Date, GSK Parkland shall revise, implement, and distribute the written Code of Conduct to all Covered Persons. GSK Parkland shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKParkland’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKParkland’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKParkland’s own Policies and Procedures; c. GSK’s the requirement that all of Parkland’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKParkland, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKParkland’s own Policies and Procedures; d. the personal obligations requirement that all of each Parkland’s Covered Person Persons shall immediately report to the Chief Quality and Safety Officer, or other appropriate individual designated by Parkland, credible allegations of patient harm and such report shall be complete, full, and honest; e. the possible consequences to both Parkland and Covered Persons of failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith Parkland’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. f. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKParkland’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Datepromulgation of any revision to the Code of Conduct, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Xxxxxxxx’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Parkland shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalizedfinalized and approved by the Board. Each Covered Person shall certify, in writing or electronicallyelectronic form, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 days after the Effective Date, GSK Par shall update and distribute the its written Code of Conduct to all employees and other Covered Persons. GSK Par shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKPar’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions; b. GSKPar’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirementsrequirements, and with GSKPar’s own Policies and Procedures; c. GSK’s the requirement that all of Par’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKPar, suspected violations of any Federal health care program requirements, FDA requirements, or of GSKPar’s own Policies and Procedures; d. the personal obligations obligation of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSKPar’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.F, and GSKPar’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within Within 120 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Par’s Code of Conduct. New Covered Persons shall receive the Code of Par Corporate Integrity Agreement Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Par shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 90 days after the Effective Date, GSK the CareAll Entities shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK The CareAll Entities shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSK’s The CareAll Entities’ commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSK’s The CareAll Entities’ requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSK’s the CareAll Entities’ own Policies and Procedures; c. GSK’s the requirement that all of the CareAll Entities’ Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKthe CareAll Entities, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSK’s the CareAll Entities’ own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSK’s the CareAll Entities’ commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the CareAll Entities’ Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK The CareAll Entities shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed Orthofix developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered Persons. GSK Orthofix shall continue to make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKOrthofix’s commitment to full compliance with all Federal health care program requirements requirements, including its commitment to prepare and submit accurate claims and to contract and enter into Arrangements consistent with such requirements; b. Orthofix’s commitment to full compliance with all FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions;Promotional and Product Services Related Functions and to market, sell, promote, research, develop, provide information about, and advertise its products in accordance with Federal health program requirements and FDA requirements. b. GSKc. Orthofix’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, and FDA Requirements, requirements and with GSKOrthofix’s own Policies and ProceduresProcedures as implemented pursuant to Section III.B.2; c. GSK’s d. the requirement that all of Orthofix’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKOrthofix, suspected violations of any Federal health care program requirements, requirements or FDA requirements, requirements or of GSKOrthofix’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKOrthofix’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, Orthofix’s Code of Conduct shall be distributed to each Covered Person and each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Orthofix’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Orthofix shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior To the extent not already completed prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 within 90 days after the Effective Date, GSK Odyssey shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK Distribution may include publishing the Code of Conduct on Odyssey’s intranet or other internal web site available to all employees and Covered Persons. If Odyssey uses such an electronic distribution method, it must notify the individuals of the distribution of the Code of Conduct in that manner and it must monitor the distribution to ensure that all appropriate individuals receive the revised Code of Conduct. Odyssey shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKOdyssey’s commitment to full compliance with all applicable Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKOdyssey’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKOdyssey’s own Policies and ProceduresProcedures as implemented pursuant to this Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of Odyssey’s Covered Persons shall be expected to report to the Compliance Officer, Officer or other appropriate individual designated by GSK, Odyssey suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKOdyssey’s own Policies and Procedures; d. the personal obligations possible consequences to both Odyssey and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, FDA requirements, requirements and GSKwith Odyssey’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKOdyssey’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the Odyssey’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Odyssey shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions to the Code of Conduct are finalized. Each Covered Person shall certify, in writing or electronicallywriting, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 60 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed Lilly developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct (known as “The Red Book”) to all Covered Persons. GSK Lilly currently requires all newly employed Covered Persons to certify in writing or electronically, that they have received, read, understood, and shall abide by Lilly’s Code of Conduct. Lilly shall continue to make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Persons. The Code of Conduct includessets forth and shall continue to set forth, or within 120 days after the Effective Date shall be revised to address at a minimum, the following: a. GSK’s x. Xxxxx’x commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC commitment to market, sell, promote, research, develop, provide information about, and advertise its products in accordance with Federal health program requirements and FDA requirements; Corporate Integrity Agreement commitment to comply with all requirements relating to the Covered Functions;Xxx Lilly Company b. GSK’s x. Xxxxx’x requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, and FDA Requirements, requirements and with GSKLilly’s own Policies and ProceduresProcedures as implemented pursuant to Section III.B (including the requirements of this CIA); c. GSK’s the requirement that all of Lilly’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKLilly, suspected violations of any Federal health care program requirements, and FDA requirements, requirements or of GSKLilly’s own Policies and Procedures; d. the personal obligations possible consequences to both Lilly and Covered Persons of each Covered Person failure to comply with Federal health care program requirements, and FDA requirements, requirements and GSKwith Lilly’s own Policies and ProceduresProcedures and the failure to report such noncompliance; and e. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKLilly’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 days after the Effective Date, the Code of Conduct shall be distributed to each Covered Person and each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Lilly’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Lilly shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalizedfinalized by the Compliance Office. Each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementAgreement Xxx Xxxxx Company

Code of Conduct. Prior to the Effective Date, GSK developed Allergan developed, implemented, and implemented distributed a written Code of Conduct. Within 120 days after the Effective Date, GSK shall distribute the written Code of Conduct to all Covered PersonsPersons who are employees. GSK Allergan shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance a condition of employment of all employees Covered Persons who are Covered Personsemployees. The Code of Conduct includessets forth and shall continue to set forth, or within 120 days after the Effective Date shall be revised to address at a minimum, the following: a. GSKAllergan’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply market, sell, promote, research, develop, provide information about, and advertise its products in accordance with all Federal health program requirements relating to the Covered Functionsand FDA requirements; b. GSKAllergan’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, and FDA Requirements, requirements and with GSKAllergan’s own Policies and ProceduresProcedures as implemented pursuant to Section III.B (including the requirements of this CIA); c. GSKAllergan’s requirement that all of Allergan’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by GSKAllergan, suspected violations by Allergan or persons acting on behalf of Allergan of any Federal health care program requirements, and FDA requirements, requirements or of GSKAllergan’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKAllergan’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplishedaccomplished within the last 150 days, within 120 days after the Effective Date, the Code of Conduct shall be distributed to each Covered Person and each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the Allergan’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. GSK Allergan shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalizedfinalized by the Corporate Compliance Department. Each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity Agreement.

Code of Conduct. Prior to the Effective Date, GSK developed and implemented a written Code of Conduct. Within 120 90 days after the Effective Date, GSK Xxxxxxxxxx Regional shall develop, implement, and distribute the a written Code of Conduct to all Covered Persons. GSK Xxxxxxxxxx Regional shall make the promotion of, and adherence to to, the Code of Conduct an element in evaluating the performance of all employees who are Covered Personsemployees. The Code of Conduct includesshall, or within 120 days after the Effective Date shall be revised to address the followingat a minimum, set forth: a. GSKx. Xxxxxxxxxx Regional’s commitment to full compliance with all Federal health care program requirements and FDA requirements, including its GlaxoSmithKline LLC Corporate Integrity Agreement commitment to comply prepare and submit accurate claims consistent with all requirements relating to the Covered Functionssuch requirements; b. GSKx. Xxxxxxxxxx Regional’s requirement that all of its Covered Persons shall be expected to comply with all applicable Federal health care program requirements, FDA Requirements, requirements and with GSKXxxxxxxxxx Regional’s own Policies and Procedures; c. GSK’s the requirement that all of Xxxxxxxxxx Regional’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by GSKXxxxxxxxxx Regional, suspected violations of any Federal health care program requirements, FDA requirements, requirements or of GSKXxxxxxxxxx Regional’s own Policies and Procedures; d. the personal obligations of each Covered Person to comply with Federal health care program requirements, FDA requirements, and GSK’s Policies and Procedures; and e. d. the right of all individuals to use the Disclosure Program described in Section III.FIII.E, and GSKXxxxxxxxxx Regional’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. To the extent not already accomplished, within 120 Within 90 days after the Effective Date, each Covered Person shall certify, in writing or electronicallyin electronic form, that he or she has received, read, understood, and shall abide by the Xxxxxxxxxx Regional’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 90 days after the Effective Date, whichever is later. GSK Xxxxxxxxxx Regional Medical Center Corporate Integrity Agreement Xxxxxxxxxx Regional shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based on such review. Any revised The Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each at least annually to all Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. GlaxoSmithKline LLC Corporate Integrity AgreementPersons.